101 related articles for article (PubMed ID: 25165995)
1. Effects of 6-(4-chlorophenoxy)-tetrazolo[5,1-a]phthalazine on anticoagulation in mice and the inhibition of experimental thrombosis in rats.
Yu HL; Zhang F; Lan T; Quan ZS
J Cardiovasc Pharmacol; 2014 Dec; 64(6):560-6. PubMed ID: 25165995
[TBL] [Abstract][Full Text] [Related]
2. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
6. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
7. Total steroidal alkaloids from Veratrum patulum L. Inhibit platelet aggregation, thrombi formation and decrease bleeding time in rats.
Song Q; Wang S; Zhao W
J Ethnopharmacol; 2012 May; 141(1):183-6. PubMed ID: 22366682
[TBL] [Abstract][Full Text] [Related]
8. [Study of a glycoprotein from Gastrodia elata: its effects of anticoagulation and antithrombosis].
Ding CS; Shen YS; Li G; Wei Z; Wei F
Zhongguo Zhong Yao Za Zhi; 2007 Jun; 32(11):1060-4. PubMed ID: 17672344
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
10. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
12. Novel role of puberty onset protein kisspeptin as an anticoagulation peptide.
Qureshi IZ; Kanwal S
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):40-9. PubMed ID: 21042204
[TBL] [Abstract][Full Text] [Related]
13. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding.
Nagakura T; Tabata K; Kira K; Hirota S; Clark R; Matsuura F; Hiyoshi H
Thromb Res; 2013 Aug; 132(2):271-9. PubMed ID: 23827699
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Wong PC; Quan ML; Crain EJ; Watson CA; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2000 Jan; 292(1):351-7. PubMed ID: 10604970
[TBL] [Abstract][Full Text] [Related]
16. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
17. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
[TBL] [Abstract][Full Text] [Related]
18. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa.
Jiang L; Wang Q; Shen S; Xiao T; Li Y
Thromb Res; 2014 Mar; 133(3):501-6. PubMed ID: 24412029
[TBL] [Abstract][Full Text] [Related]
19. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
20. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
Ju CW; Wang LS; Yang X; Ma GS; Hua ZC; Gao XY
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):540-3. PubMed ID: 15569533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
